27143-07-3|Ethyl 2-chloro-2-(2-(4-methoxyphenyl)hydrazono)acetate| Ambeed

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Structure of 27143-07-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size

Price

VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock

{[ item.pr_size ]}

Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

Quality Control of [ 27143-07-3 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 27143-07-3 ]

CAS No. :	27143-07-3
Formula :	C₁₁H₁₃ClN₂O₃
M.W :	256.69
SMILES Code :	O=C(OCC)/C(Cl)=N/NC1=CC=C(OC)C=C1
MDL No. :	MFCD02852962

Safety of [ 27143-07-3 ]

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H301-H311-H331-H341
Precautionary Statements:	P201-P202-P261-P264-P270-P271-P280-P302+P352-P304+P340-P308+P313-P310-P330-P361-P403+P233-P405-P501
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

Computational Chemistry of [ 27143-07-3 ] Show Less

Physicochemical Properties

Num. heavy atoms	17
Num. arom. heavy atoms	6
Fraction Csp3	0.27
Num. rotatable bonds	6
Num. H-bond acceptors	4.0
Num. H-bond donors	1.0
Molar Refractivity	66.43
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	59.92 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.73
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	4.1
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.03
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.56
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.08
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.5

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.88
Solubility	0.0339 mg/ml ; 0.000132 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-5.06
Solubility	0.00221 mg/ml ; 0.00000863 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.77
Solubility	0.0435 mg/ml ; 0.000169 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	Yes
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-4.95 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.64

Application In Synthesis of [ 27143-07-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 27143-07-3 ]

[ 27143-07-3 ] Synthesis Path-Downstream 1~55

1
[ 56886-06-7 ]
[ 27143-07-3 ]
[ 56885-95-1 ]

References: [1]Journal of Heterocyclic Chemistry,1975,vol. 12,p. 401 - 403.

2
[ 104-94-9 ]
[ 105-39-5 ]
[ 27143-07-3 ]

References: [1]Farmaco, Edizione Scientifica,1985,vol. 40,p. 259 - 271.

3
[ 123-54-6 ]
[ 27143-07-3 ]
[ 63514-81-8 ]

References: [1]Farmaco, Edizione Scientifica,1985,vol. 40,p. 259 - 271.

4
[ 27143-07-3 ]
[ 109399-37-3 ]
[ 132679-97-1 ]

References: [1]Bulletin of the Academy of Sciences of the USSR Division of Chemical Science,1990,vol. 39,p. 2388 - 2390.
Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya,1990,p. 2635 - 2637.

5
[ 61385-80-6 ]
[ 27143-07-3 ]
5-methyl-4-methoxy-1-(4-methoxyphenyl)-3-ethoxycarbonyl-1,4,5,6-tetrahydro-1,2,5,4λ⁵-triazaphosphorine-4,6-dione [ No CAS ]

References: [1]Russian Journal of General Chemistry,1993,vol. 63,p. 569 - 577.
Zhurnal Obshchei Khimii,1993,vol. 63,p. 810 - 824.

6
[ 61385-80-6 ]
[ 27143-07-3 ]
4-hydroxy-5-methyl-1-(4-methoxyphenyl)-3-carbonyl-1,4,5,6-tetrahydro-1,2,5,4λ⁵-triazaphosphorine-4,6-dione dipotassium salt [ No CAS ]

References: [1]Russian Journal of General Chemistry,1993,vol. 63,p. 569 - 577.
Zhurnal Obshchei Khimii,1993,vol. 63,p. 810 - 824.

7
[ 43052-77-3 ]
[ 27143-07-3 ]
8,9-Dimethoxy-2-[(4-methoxy-phenyl)-hydrazono]-3-oxo-2,3,5,6-tetrahydro-pyrrolo[2,1-a]isoquinoline-1-carbonitrile [ No CAS ]

References: [1]Journal of Chemical Research - Part S,1996,p. 292 - 293.

8
[ 95-54-5 ]
[ 27143-07-3 ]
[ 204512-13-0 ]

References: [1]Archiv der Pharmazie,1997,vol. 330,p. 387 - 391.
[2]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

10
[ 137-07-5 ]
[ 27143-07-3 ]
2-[(4-methoxy-phenyl)-hydrazono]-4H-benzo[1,4]thiazin-3-one [ No CAS ]

References: [1]Journal of Heterocyclic Chemistry,2003,vol. 40,p. 207 - 212.

11
[ 137-07-5 ]
[ 27143-07-3 ]
C₁₇H₁₉N₃O₃S [ No CAS ]

References: [1]Journal of Heterocyclic Chemistry,2003,vol. 40,p. 207 - 212.

12
[ 27143-07-3 ]
[ 3694-52-8 ]
[ 733746-35-5 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

13
[ 53744-76-6 ]
[ 27143-07-3 ]
{5-[(4-methoxy-phenyl)-hydrazono]-4-oxo-3-phenyl-thiazolidin-2-ylidene}-acetonitrile [ No CAS ]

References: [1]Chemistry of Heterocyclic Compounds,2007,vol. 43,p. 93 - 97.

14
[ 53744-76-6 ]
[ 27143-07-3 ]
[ 89844-62-2 ]

References: [1]Chemistry of Heterocyclic Compounds,2007,vol. 43,p. 93 - 97.

15
[ 27143-07-3 ]
[ 204511-94-4 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.
[2]Archiv der Pharmazie,1997,vol. 330,p. 387 - 391.

16
[ 27143-07-3 ]
[ 204511-87-5 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.
[2]Archiv der Pharmazie,1997,vol. 330,p. 387 - 391.

17
[ 27143-07-3 ]
[ 269716-99-6 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

18
[ 27143-07-3 ]
[ 269716-68-9 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

19
[ 27143-07-3 ]
4-amino-2-(4-hydroxyphenyl)-[1,2,4]triazolo[4,3-a]quinoxalin-1(2H)-one [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

20
[ 27143-07-3 ]
6-amino-2-(4-methoxy-phenyl)-2H,5H-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

21
[ 27143-07-3 ]
[ 733746-39-9 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

22
[ 27143-07-3 ]
acetic acid 4-(1,4-dioxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-2-yl)-phenyl ester [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

23
[ 27143-07-3 ]
[ 733746-31-1 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

24
[ 27143-07-3 ]
[ 733746-20-8 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

25
[ 27143-07-3 ]
[ 733746-29-7 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

26
[ 27143-07-3 ]
[ 733746-19-5 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

27
[ 27143-07-3 ]
6-amino-2-(4-hydroxy-phenyl)-2H,5H-[1,2,4]triazolo[4,3-a]quinoxaline-1,4-dione [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

28
[ 27143-07-3 ]
4,6-diamino-2-(4-hydroxy-phenyl)-2H-[1,2,4]triazolo[4,3-a]quinoxalin-1-one [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

29
[ 27143-07-3 ]
4-amino-2-(4-hydroxyphenyl)-6-nitro-[1,2,4]triazolo[4,3-a]quinoxalin-1(2H)-one [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

30
[ 27143-07-3 ]
[ 733746-40-2 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

31
[ 27143-07-3 ]
[ 733746-21-9 ]

References: [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 3580 - 3590.

32
[ 27143-07-3 ]
4-hydroxy-5-methyl-3-methoxycarbonyl-1-phenyl-1,4,5,6-tetrahydro-1,2,5,4λ⁵-triazaphosphorine-4,6-dione [ No CAS ]

References: [1]Russian Journal of General Chemistry,1993,vol. 63,p. 569 - 577.
Zhurnal Obshchei Khimii,1993,vol. 63,p. 810 - 824.

33
[ 27143-07-3 ]
1-(1-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl)ethan-1-one [ No CAS ]

References: [1]Farmaco, Edizione Scientifica,1985,vol. 40,p. 259 - 271.

34
[ 27143-07-3 ]
[ 96723-39-6 ]

References: [1]Farmaco, Edizione Scientifica,1985,vol. 40,p. 259 - 271.

35
3-chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one [ No CAS ]
[ 27143-07-3 ]
C₂₂H₂₂N₄O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In water; toluene; at 20 - 100℃;	Example 3; The starting hydrazone (6.5 kg) and tetrahydropyridone (6.0 kg) were charged to a 50 gal glass-lined reactor. To the reactor was added toluene (44.9 kg), and the batch was heated to 90° C. Triethylamine (7.2 kg) was charged to the reactor from a pressure cylinder over 90 minutes, maintaining the batch temperature below 100° C. After the addition, the transfer line was flushed with toluene (1 kg). The reaction mass was mixed at 90° C. for two hours and then cooled to 40° C. for sampling. Purified water (11 L) was added keeping the temperature above 35° C. (5 min). The reaction mixture was cooled to 20° C. over two hours and stirred at 20° C. overnight. The reaction mixture was centrifuged (20 min). To the reactor was charged 42 L of purified water and this water was discharged to the centrifuge. Two distinct liquid layers were observed in the centrate, indicating that the cake had not been fully deliquored. Isopropanol (9.5 kg) was charged to the reactor and then to the centrifuge. This centrate contained two layers as well. The wet cake (10.6 kg) was transferred to drying trays covered with FEP liners. The cake was dried at 50° C. for 33.5 hours to give 9.2 kg of dried product.

References: [1]Patent: US2006/69258,2006,A1 .Location in patent: Page/Page column 13-14.

36
[ 27143-07-3 ]
[ 5525-95-1 ]
[ 1156538-63-4 ]

References: [1]Russian Journal of General Chemistry,2008,vol. 78,p. 1172 - 1176.

37
[ 27143-07-3 ]
1-(ethoxycarbonylmethylene)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline [ No CAS ]
[ 1161946-75-3 ]

References: [1]Heterocycles,2009,vol. 78,p. 1507 - 1522.

38
[ 27143-07-3 ]
1-(ethoxycarbonylmethylene)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline [ No CAS ]
[ 1161946-83-3 ]

References: [1]Heterocycles,2009,vol. 78,p. 1507 - 1522.

39
[ 452-58-4 ]
[ 27143-07-3 ]
[ 1144161-09-0 ]

References: [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 2407 - 2419.

40
[ 73430-27-0 ]
[ 27143-07-3 ]
[ 1190305-98-6 ]

References: [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 7640 - 7652.

41
[ 638-07-3 ]
[ 104-94-9 ]
[ 27143-07-3 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLES; Example 1; To a 30 gallon glass-lined reactor was charged water (26 L) and p-anisidine (8.5 kg; 68.1 moles). The reactor was inerted, and 20.1 kg 37percent HCl (3 eq.) were charged to the reactor followed by a line flush of 2 L purified water. The batch was heated to 40° C. and checked to ensure dissolution of p-anisidine (total time at 40° C. was 25 minutes). The batch was cooled to -2° C. and 40percent aqueous sodium nitrite (12.0 kg; 69.5 moles) was charged to the reactor while keeping the temperature at -2+/-3° C. The addition time for the aqueous sodium nitrite was 35 minutes. The sodium nitrite line was flushed with 2 L of purified water. The reaction mixture was sampled and analyzed for reaction completion. To the batch was added 3.0 kg of 11percent aqueous sulfamic acid via nitrogen pressure, keeping the reactor contents at -2+/-3° C. In a separate 100 gallon glass-lined reactor, 28 L of purified water was charged followed by 11.2 kg of solid sodium acetate. The reactor was inerted, and the batch was heated to 35° C. until the solid dissolved. The batch was cooled to 15° C. and 18 kg acetone was added to the reactor. To the reactor was added 12.4 kg ethyl-2-chloroacetoacetate by deadhead vacuum, followed by 2.1 kg of acetone to flush the addition line. The batch was cooled to -2+/-3° C. The contents of the above 30 gallon reactor were then transferred to the 100 gallon reactor keeping the batch in the 100 gallon reactor at -2+/-3° C. The transfer time was 45 minutes. The transfer line was flushed with 5.0 kg of acetone, and the batch was allowed to mix for one hour. To the reactor was charged 32.0 kg of acetone, and the batch was mixed for 15 minutes. The batch was allowed to settle for 30 minutes. To the reactor was charged 10.2 kg of acetone and the batch was mixed for 5 minutes. Agitation was stopped and the batch was allowed to settle for 30 minutes. The aqueous phase was discharged to a drum (140.2 kg; waste). To the reactor was charged 13.4 kg of methanol, controlling the reactor temperature to 0+/-3° C. The batch was held at 0+/-3° C. and sampled every hour until the reaction was complete. To the reactor was charged 75 L of purified water. The batch was heated to 5+/-5° C. and allowed to mix for 15 minutes. The batch was isolated using a portable centrifuge with a 5-7 micron polypropylene bag. The isolation lasted 10 minutes (109 kg of centrate). To the reactor was charged 26 L of purified water and 20.2 kg of methanol. The mixture was cooled to 5+/-3° C. and then discharged to the centrifuge to wash the cake. The wet cake (14.5 kg) was transferred to drying trays covered with FEP liners. The cake was dried at 40° C. for 80 hours to give 13.8 kg of the desired product.

References: [1]Patent: US2006/69258,2006,A1 .Location in patent: Page/Page column 11-12.

42
3-chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-[⁽¹⁴⁾C]one [ No CAS ]
[ 27143-07-3 ]
ethyl 1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-[⁽¹⁴⁾C]oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate [ No CAS ]

References: [1]Journal of labelled compounds and radiopharmaceuticals,2010,vol. 53,p. 363 - 367.
[2]Journal of labelled compounds and radiopharmaceuticals,2011,vol. 54,p. 418 - 425.

43
[ 2295-31-0 ]
[ 27143-07-3 ]
[ 1049122-22-6 ]

References: [1]Synthesis,2011,p. 1799 - 1803.

44
[ 104-94-9 ]
[ 609-15-4 ]
[ 27143-07-3 ]

Yield	Reaction Conditions	Operation in experiment
89%		100 g (0.81 mol) of the starting material (3) was added to 400 ml of water at room temperature,To the reaction solution was added dropwise 270 ml (3.24 mol) of concentrated hydrochloric acid.After the dropwise addition, 115 g (1.62O1) of a mixed solution of sodium nitrite and 460 ml of water was added dropwise to the reaction solution, and the temperature control was carried out at -5 to 10C.Drop control, control the temperature at -5 ~ -10 ° C reaction 30min.Then, 135 ml (0.97 mol 1) of the reaction solution was added dropwise to the reaction solution,A mixed solution of ethyl dichloroacetoacetate and 135 ml of methanol,The temperature during the dropwise process is controlled at -5 to 10 ° C.After completion of the reaction, a mixed solution of 207 g (2.43 mol) of anhydrous sodium acetate and 514 ml of water was added dropwise to the reaction solution,The temperature is maintained at -5 to 10 ° C during the dropwise addition. Drop finished, temperature control at _10 ° C, reaction 2h.Then transferred to room temperature, allowed to stand overnight, with a brown solid precipitated, filtered and the filter cake was washed with anhydrous methanol (2 x 300ml).To give 186.9 g of a yellow solid (theoretical yield of 208. lg) in a yield of 89percent
85.0%		General procedure: Commercially available substituted aniline (63.4mmol) was portionwise added to a solution of concentrated HCl (13mL), ethanol (20mL) and water (7mL). To the above mixture was added dropwise a solution of NaNO2 (4.69g, 69.7mmol) in water (15mL) at 0?5°C. After the completion of addition, the reaction mixture was stirred at this temperature for 30min, and then added into a mixture of ethyl 2-chloroacetoacetate (10.88g, 63.4mmol), anhydrous sodium acetate (15.60g, 190.10mmol), and water (90mL) at 0°C. The reaction mixture was stirred at 0°C for 10min and then at room temperature for 4h. The solid which precipitated was collected by filtration and recrystallized from ethanol to afford light yellow solids (21a?21m) in 75.2?90percent yields. 6.3.4 Ethyl 2-chloro-2-(2-(4-methoxyphenyl)hydrazono)acetate (21d) Yellow solid; Yield: 85.0percent; M.p.: 96.6-98.5 °C; MS (ESI) m/z(percent):279.1 [M+Na]+, 535.1 [2M+Na]+.
73.6%		In 250 mLTo a three-necked flask was added p-methoxyaniline (13.5 g, 0.11 mol) Water (56 ml), concentrated hydrochloric acid (28 ml),Stirred and dissolved, cooled to -5°C ,NaNO2 (7.9g, 0.12mol) aqueous solution was added dropwise, the temperature was controlled below 0°C ,Reaction below 0 °C for 30min. A 500 mL three-necked flask was charged with ethyl 2-chloroacetoacetate (18 g, 0.11 mol) Ethanol 270mL,Water 30mL, cooled to -5°C ,Sodium acetate (13.5 g, 0.16 mol) was added.Then make the above prepared diazonium salt solution into the anti-drop Should be the system, the control temperature is below 0°C . After dropping at room temperature for 4h. The reaction mixture was poured into 1 L of water and stirred until a large amount of solid was obtained After the precipitation was filtered off to give the product, a yellow solid, 20.6g, m. p. 106-109 °C, yield 73.6percent.

50.4%	With hydrogenchloride; sodium acetate; sodium nitrite; In ethanol; water; at -5 - 20℃; for 7h;	Under room temperature, will be sequentially 4-methoxyaniline (30.0 g, 244 mmol) and water (100 ml) added to a reaction flask. Stirring of the obtained mixture, the lower the temperature to -5 to 0 °C. Then to the adding concentrated hydrochloric acid (35 ml) and sodium nitrite solution (50 ml). After the completion of the dropping, preserving heat and stirring the obtained mixture of 0.5 hours, then dropwise 2-chloro-3-oxo butyric acid ethyl ester (40.2 g, 244 mmol) of ethanol solution (200 ml), and sodium acetate (60.0 g, 732 mmol) aqueous solution (500 ml). After the completion of the dropping, at -5 to 0 °C, to the stirring mixture of 0.5 hours. Furthermore, the obtained mixture to room temperature, stirring for 6 hours. After the reaction, filtration, vacuum drying, silica gel column chromatography (PE:EA=10:1) to obtain 31.6 g product, in other words 2-chloro-2 - (2 - (4-methoxyphenyl) hydrazono) ethyl acetate (yield 50.4percent).
19%		4-methoxy-aniline (2k) (24.6 g, 0.2 mol) was dissolved in hydrochloric acid (50 mL, 0.2mol, 12N) of water (100 mL) was cooled to 0 ° C, was slowly dropwise sodium nitrite (16.6 g, 0.24 mol) in water (80 mL) solution, after the addition was complete, 0 ° C for 30 minutes, then was added sodium acetate (328 g, 0.40 mol) adjusting the reaction solution pH = 5 ~ 6, maintaining 0 ° C, was added dropwise ethyl 2-chloroacetoacetate (32.9 g, 0.2 mol) in methanol (80 mL) solution, after the addition was complete, maintaining 0. C for 1 hour. To the reaction solution was added ethyl acetate (200 mL x 2) and the combined organic phases, the organic phase was washed with saturated brine QOO mL xl), dried over anhydrous sodium sulfate, and concentrated under reduced pressure, the residue was purified by silica gel column chromatography ( ethyl acetate / petroleum ether (v / v) = 1: 50-1: 10) to give the title compound 2-chloro-2- (2- (4-methoxyphenyl) hydrazone yl) acetate (21) , as a yellow solid (19.5 g, 19percent yield).
		Example 3. Synthesis of a compound of formula (IV): Chloro[(4- methoxyphenyl)hydrazono] acetic acid ethyl ester (IV)IV p-anisidine (31.02 g, 0.252 mol) in 100 ml of H2O is suspended in a 250 ml 4-necked flask equipped with coolant, thermometer, dropping funnel and magnetic stirrer, and cooled to 0°C in an ice bath. 60 ml of 37percent HC1 is added, followed by a solution of NaNO2 (20.95 g, 0.307 mol) in 50 ml of H2O, through a dropping funnel, maintaining the temperature below 5°C. After the addition the mixture is left under stirring at between 0 and 5°C for lh, and the solution obtained is added at 0°C to a solution containing ethyl-2- chloroacetoacetate (41.65 g, 0.254 mol), AcONa (47.84 g, 0.583 mol), AcOEt (200 ml) and H2O (100 ml). The biphasic system is stirred at between 0 and 5°C for lh, and then at about 25 °C for 16h. The phases are then separated and the organic phase is washed with a saturated solution of NaHCO3 (4x80 ml), anhydrified on Na2SO4, filtered and evaporated under low pressure. The compound of formula (IV) is obtained as a solid (about 57 g), which is used for the next stage without further purification.1H NMR (300 MHz, CDC13): 68.24 (1H, s, N-H), 7.16 (2H, dd, Jo=9.0Hz, Ar-H),6.88 (2H, dd, Jo=9.0 Hz, Ar-H), 4.37 (2H, q, J=7.2 Hz, COOCH2CH3), 3.79 (3H, s, Ar-OCH3), 1.39 (3H, t, J=7.2 Hz, COOCH2CH3).
105 g		Example 5Preparation of ethyl 2-chloro-2-(2-(4-methoxyphenyl)hydrazono)acetateStep-i: Water (600 ml) was added to p-anisidine (100 g) at room temperature and the resulting mixture was cooled to 10°C, followed by the addition of concentrated hydrochloric acid (133.5 g). The resulting mixture was cooled to ?5°C to 0°C, followed by portion-wise addition of 40percent aqueous sodium nitrite solution (67.2 g in 175 ml of water) over a period of 45 minutes to 1 hour. The resulting mass was stirred for 1 hour 30 minutes at ?5°C to0°C, followed by slow addition of 11percent sulfamic acid solution (35 g in 325 ml of water) over a period of 1 hour to 1 hour 30 minutes to produce a reaction mass (first part).Step-2:Sodium acetate (146 g) was added to water (300 ml) at room temperature and then stirred for 10 minutes to 15 minutes, followed by the addition of ethyl 2-chloroacetoacetate (160.4g) and acetone (300 ml) at room temperature to form a reaction mixture. The resulting mixture was cooled to 0°C (second part). The resulting mixture (second part) was added to the reaction mass (first part) obtained in step-i at ?5°C to 0°C and then stirred for 1 hour at the same temperature. Acetone (200 ml) was added to the resulting mass and then stirred for 30 minutes at ?5°C to 0°C. The resulting mass was settled for 5 hours at ?5°C to 0°Cand then filtered the solid. Methanol (150 ml) was added to the resulting solid at room temperature and then stirred for 2 hours at the same temperature. The separated solid was filtered, washed with methanol (50 ml) and then dried the material at 25°C for 24 hours to produce 105 g of ethyl 2-chloro-2-(2-(4-methoxyphenyl)hydrazono)acetate (Purity by HPLC: 96percent).

References: [1]Patent: CN104513239,2017,B .Location in patent: Paragraph 0197; 0238; 0243; 0244.
[2]European Journal of Medicinal Chemistry,2016,vol. 123,p. 431 - 446.
[3]Patent: CN107400131,2017,A .Location in patent: Paragraph 0026; 0031; 0042-0044.
[4]Patent: CN105384739,2016,A .Location in patent: Paragraph 0391; 0392; 0393.
[5]Patent: CN104395312,2016,B .Location in patent: Paragraph 0396; 0451-0455; 0501; 0502-0506.
[6]Synthesis,2011,p. 1799 - 1803.
[7]Patent: WO2012/168364,2012,A1 .Location in patent: Page/Page column 16-17.
[8]Patent: WO2015/177801,2015,A1 .Location in patent: Page/Page column 25; 26.
[9]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 2800 - 2810.

45
[ 27143-07-3 ]
apixaban [ No CAS ]

References: [1]Patent: WO2012/168364,2012,A1 .
[2]Patent: WO2014/75648,2014,A1 .
[3]Patent: WO2014/75648,2014,A1 .
[4]Patent: WO2015/177801,2015,A1 .
[5]Patent: WO2015/177801,2015,A1 .
[6]Patent: CN104045637,2016,B .
[7]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 2800 - 2810.
[8]Patent: CN107400131,2017,A .
[9]Patent: CN107955002,2018,A .
[10]Patent: WO2018/127936,2018,A1 .
[11]Patent: WO2018/127936,2018,A1 .
[12]Patent: WO2018/127936,2018,A1 .
[13]Patent: WO2018/127936,2018,A1 .
[14]Patent: WO2015/111073,2015,A3 .

46
[ 27143-07-3 ]
[ 503614-91-3 ]

47
[ 1415831-80-9 ]
[ 27143-07-3 ]
[ 473927-64-9 ]

Yield	Reaction Conditions	Operation in experiment
63%		Example 4. Synthesis of a compound of formula (II): l-(4- methoxyphenyl)-6-(4-iodophenyl)-7-oxo-4,5,6,7-tetrahydro-l//- pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl esterIII IV IICompound (IV) (0.82 g, 3.19 mmol) is dissolved in 5 ml of AcOEt in a ml 3-necked flask equipped with coolant, thermometer and magnetic stirrer, in nitrogen atmosphere, and cooled to 0° with an ice bath. Compound (III) (1.02 g, 2.63 mmol) and triethylamine (0.89 ml, 6.40 mmol) are added. When the additions have been completed, the reaction is heated to reflux temperature for 3h, after which another portion of compound (IV) (350 mg) and triethylamine (0.25 ml) are added. When compound (III) has completely disappeared, the end-of-reaction mixture is cooled to 0°C, treated with a solution of HC1 (1.80 g of 37percent HC1 in 3.20 g of H2O) and maintained under stirring at room temperature overnight. A solid precipitates, which is filtered through a Buchner funnel and washed with 5 ml of a 1 : 1 solution of AcOEt and isopropanol. The compound of formula (II) is obtained as a solid (0.85 g, yield 63percent).1H NMR (300 MHz, CDC13): 67.67 (2H, dd, J0=8.7 Hz, Ar-H), 7.46 (2H, dd, Jo=9.0 Hz, Ar-H), 7.06 (2H, dd, Jo=9.0 Hz, Ar-H), 6.90 (2H, dd, Jo=9.0 Hz, Ar-H), 4.45 (2H, q, J=7.2 Hz, 4.09 (2H, t, J=6.6 Hz, CH2(3/4N), 3.81 (3H, s, Ar-OCH3), 3.32 (2H, t, J=6.6 Hz, (3/4CH2N), 1.43 (3H, t, J=7.3 Hz, COOCH2CH3).

References: [1]Patent: WO2012/168364,2012,A1 .Location in patent: Page/Page column 17-18.

48
[ 1519975-07-5 ]
[ 27143-07-3 ]
[ 1519975-44-0 ]

Yield	Reaction Conditions	Operation in experiment
78%	With triethylamine; In ethanol;Reflux;	General procedure: General procedure: To a mixture of the thiazolylthiourea derivative 2 (1mmol, 0.421g) and the appropriate hydrazonoyl chlorides 3, 7a?e and 14a?e (1mmol) in absolute ethanol (10 mL), triethylamine (0.1 mL) was added and the resulting mixture was refluxed for 6?10 h, then left to cool to room temperature. The solid formed was collected by filtration, washed with ethanol, dried and finally recrystallized from DMF/EtOH to afford the corresponding thiazolylimino-1,3,4-thiadiazole derivatives 6, 10a?e and 17a?e, respectively. The physical properties and spectral data of the obtained products are listed below.

References: [1]European Journal of Medicinal Chemistry,2013,vol. 70,p. 740 - 749.

49
[ 27143-07-3 ]
[ 503614-92-4 ]

References: [1]Patent: WO2014/75648,2014,A1 .
[2]Patent: CN104045637,2016,B .
[3]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 2800 - 2810.
[4]Patent: CN107400131,2017,A .

50
[ 473927-69-4 ]
[ 27143-07-3 ]
[ 473927-64-9 ]

Yield	Reaction Conditions	Operation in experiment
75%	With triethylamine; In ethyl acetate; at 0℃; for 2h;Inert atmosphere; Cooling with ice; Reflux;	The preparation was carried out in an inert atmosphere (argon). 2-Chloro-2-[2-(4- methoxyphenyl)hydrazono] acetic acid ethyl ester (14.1 g; 0.055 mol) was dissolved in 140 ml of ethyl acetate. The solution was cooled to 0-5°C in an iced water bath. The solution being stirred, 1-(4-iodophenyl)-3-morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one (21.1 g; 0.055 mol) was added in portions. After stirring up, triethylamine (11.1 g; 0.110 mol) was added dropwise to the reaction mixture at 0-5 °C. The cooling of the reaction mixture was interrupted and the temperature was left to rise to the room level. Then, heating was started up to reflux. The reflux temperature of the reaction mixture was maintained for ca. 120 min. Completion of the reaction was monitored by means of HPLC. The reaction mixture was cooled to 0-5°C again and concentrated hydrochloric acid (27.5 ml; 0.275 mol) diluted with distilled water in the 1 :1 ratio was slowly added dropwise. Being cooled, the reaction mixture was stirred for ca. 1 h. Then, another 55 ml of water was added and the resulting suspension was stirred for another 2 h while being cooled. The separated product was isolated by filtration and dried in vacuo at 50°C for 24 h. The product III was obtained in the yield of 21.3 g; i.e. 75 percent and HPLC quality of 95 percent.
30.4%		Step-2: Ethyl 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H- pyrazolo [3,4-cJ pyridine-3-carboxylate 1 -(4-Iodophenyl)-3 -morpholine-5,6-dihydro-2H-pyridin-2-one (100 g, obtained in step-i), <strong>[27143-07-3]ethyl 2-chloro-2-(2-(4-methoxyphenyl)hydrazono)acetate</strong> (100 g) and triethylamine (131.6g) were added to toluene (1000 ml) at room temperature. The resulting mixture was heated to reflux and then stirred for 2 hours at reflux. The reaction mass was cooled to room temperature, followed by filtration and then washing with toluene (50 ml x 2). The resulting toluene layer was washed with water (200 ml x 2), followed by distillation of toluene layer under vacuum at 90°C to obtain a residue (164 g). 4N Hydrochloric acid (79.2g) and dichloromethane (315 ml) were added to the resulting residue and then stirred for 2 hours at room temperature. The reaction mass was washed with 2percent sodium bicarbonate solution (200 ml), followed by washing with water (200 ml) and then adjusting the pH to 6. The resulting dichioromethane layer was treated with carbon (10 g), followed by distillation under vacuum at 55°C to obtain a residue (175 g). Acetone (200 ml) was addedto the resulting residue and then stirred for 30 minutes at room temperature. The resulting mass was cooled to 0-5°C for 30 minutes and then stirred for 30 minutes. The separated solid was filtered, washed with chilled acetone (70 ml) and then dried the material at 65°C for 3 hours to produce 102 g of ethyl 6-(4-iodophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5,6,7- tetrahydro- 1 H-pyrazolo[3 ,4-c]pyridine-3 -carboxylate (Purity by HPLC: 99percent; overall yield:30.4percent).

References: [1]Patent: WO2014/75648,2014,A1 .Location in patent: Page/Page column 11.
[2]Patent: WO2015/177801,2015,A1 .Location in patent: Page/Page column 23.

Yield	Reaction Conditions	Operation in experiment
		General procedure: [00295] 29A. (4-methoxyphenyl)carbonocyanidohydrazonic chloride: A solution of NaN02 (8.89 g, 125 mmol) in water (55 mL) was added to a stirred mixture oip- anisidine (14.8 g, 119 mmol), aq. HC1, 37percent (37 mL), and water (92 mL) cooled to -5 °C. The resulting mixture was stirred for 20 min and then 2-chloro-3-oxobutanenitrile (6.34 g, 53.9 mmol), EtOH (92 mL), NaOAc (29.4 g, 355 mmol), and water (368 mL) were added sequentially. The reaction mixture was allowed to warm to rt and stirred for an additional 5.0 h. The reaction mixture was filtered and the collected solid was thoroughly rinsed with water. The sticky solid obtained above was dissolved in CH2Cl2 (300 mL). The solution was dried (Na2S04), filtered, and concentrated to provide 29A (brown solid, 1 1.2 g, 37.8 mmol, 70 percent yield). LC-MS Anal.Calc'd for C9H8C1N30 209.63, found [M+H] 210.0.

52
[ 27143-07-3 ]
[ 1610369-69-1 ]

References: [1]Patent: WO2014/78608,2014,A1 .

53
[ 27143-07-3 ]
[ 1610369-70-4 ]

References: [1]Patent: WO2014/78608,2014,A1 .

54
[ 27143-07-3 ]
[ 1610369-71-5 ]

References: [1]Patent: WO2014/78608,2014,A1 .

55
[ 27143-07-3 ]
[ 1610369-72-6 ]

References: [1]Patent: WO2014/78608,2014,A1 .

Historical Records

Technical Information

• Acyl Group Substitution • Alkyl Halide Occurrence • Benzylic Oxidation • Birch Reduction • Blanc Chloromethylation • Bouveault-Blanc Reduction • Buchwald-Hartwig C-N Bond and C-O Bond Formation Reactions • Catalytic Hydrogenation • Chan-Lam Coupling Reaction • Complex Metal Hydride Reductions • Ester Cleavage • Friedel-Crafts Reaction • General Reactivity • Grignard Reaction • Hiyama Cross-Coupling Reaction • Hydride Reductions • Hydrogenolysis of Benzyl Ether • Kinetics of Alkyl Halides • Kumada Cross-Coupling Reaction • Leuckart-Wallach Reaction • Mannich Reaction • Nomenclature of Ethers • Petasis Reaction • Preparation of Alkylbenzene • Preparation of Amines • Preparation of Ethers • Reactions of Alkyl Halides with Reducing Metals • Reactions of Amines • Reactions of Benzene and Substituted Benzenes • Reactions of Ethers • Reactions with Organometallic Reagents • Specialized Acylation Reagents-Carbodiimides and Related Reagents • Specialized Acylation Reagents-Vilsmeier Reagent • Stille Coupling • Substitution and Elimination Reactions of Alkyl Halides • Suzuki Coupling • Ugi Reaction • Vilsmeier-Haack Reaction

Pharmaceutical Intermediates of
[ 27143-07-3 ]

Apixaban Related Intermediates

[385425-15-0]

1-(4-Iodophenyl)piperidin-2-one

[536759-91-8]

Ethyl 1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate

[503614-92-4]

1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid

[545445-40-7]

3-Morpholino-5,6-dihydropyridin-2(1H)-one

[38560-30-4]

1-(4-Nitrophenyl)piperidin-2-one

Related Functional Groups of
[ 27143-07-3 ]

Aryls

A107159 [27069-16-5]

5-(4-Methoxyphenyl)-1H-pyrazole-3-carboxylic acid

Similarity: 0.57

A278921 [890591-64-7]

3-(3-Methoxyphenyl)-1H-pyrazole-5-carboxylic acid

Similarity: 0.57

A202494 [2095779-74-9]

6-Chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

Similarity: 0.56

A183777 [865887-11-2]

6-Benzyloxy-1H-indazole-3-carboxylic acid

Similarity: 0.56

A186435 [1257877-12-5]

5-(6-Methoxynaphthalen-2-yl)-1H-pyrazole-3-carboxylic acid

Similarity: 0.55

Chlorides

A202494 [2095779-74-9]

6-Chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

Similarity: 0.56

A217800 [1446410-04-3]

3-Chloro-5-methoxy-1-methyl-1H-indazole

Similarity: 0.56

A150728 [1082041-58-4]

5-Chloro-6-methoxy-1H-indazole

Similarity: 0.55

A187391 [1780480-20-7]

3-Chloro-4-methoxy-1-methyl-1H-indazole

Similarity: 0.54

Ethers

A122958 [865887-07-6]

Methyl 4-methoxy-1H-indazole-3-carboxylate

Similarity: 0.57

A107159 [27069-16-5]

5-(4-Methoxyphenyl)-1H-pyrazole-3-carboxylic acid

Similarity: 0.57

A278921 [890591-64-7]

3-(3-Methoxyphenyl)-1H-pyrazole-5-carboxylic acid

Similarity: 0.57

A202494 [2095779-74-9]

6-Chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

Similarity: 0.56

A217800 [1446410-04-3]

3-Chloro-5-methoxy-1-methyl-1H-indazole

Similarity: 0.56

Esters

A122958 [865887-07-6]

Methyl 4-methoxy-1H-indazole-3-carboxylate

Similarity: 0.57

A393356 [115315-95-2]

Ethyl 1-phenyl-1H-pyrazole-3-carboxylate

Similarity: 0.53

A130109 [909717-95-9]

Ethyl 4-methoxypyrazolo[1,5-a]pyridine-3-carboxylate

Similarity: 0.52

A129797 [4498-68-4]

Ethyl 1H-indazole-3-carboxylate

Similarity: 0.52

A126930 [3597-63-5]

3-Hydroxy-2H-benzo[b][1,4]oxazin-2-one

Similarity: 0.52

Amines

A188510 [60481-02-9]

(4-Phenoxyphenyl)hydrazine hydrochloride

Similarity: 0.55

A333293 [1190305-94-2]

4-Amino-1-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid

Similarity: 0.54

A184414 [19501-58-7]

4-Methoxyphenylhydrazine hydrochloride

Similarity: 0.54

A236316 [39232-91-2]

3-Methoxyphenylhydrazine hydrochloride

Similarity: 0.54

A116063 [104033-62-7]

(4-Isopropoxyphenyl)hydrazine hydrochloride

Similarity: 0.54

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 27143-07-3

{[proInfo.proName]}

CAS No.: 27143-07-3

Alternative Products

Product Details of [ 27143-07-3 ]

Safety of [ 27143-07-3 ]

Computational Chemistry of [ 27143-07-3 ] Show Less

Physicochemical Properties

Lipophilicity

Water Solubility

Pharmacokinetics

Druglikeness

Medicinal Chemistry

Application In Synthesis of [ 27143-07-3 ]

[ 27143-07-3 ] Synthesis Path-Downstream 1~55

Related Products

Historical Records

Technical Information

Categories

Pharmaceutical Intermediates of
[ 27143-07-3 ]

Apixaban Related Intermediates

Related Functional Groups of
[ 27143-07-3 ]

Aryls

Chlorides

Ethers

Esters

Amines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

{[proInfo.proName]}

CAS No.: 27143-07-3

{[proInfo.proName]}

CAS No.: 27143-07-3

Alternative Products

Product Details of [ 27143-07-3 ]

Safety of [ 27143-07-3 ]

Computational Chemistry of [ 27143-07-3 ] Show Less

Physicochemical Properties

Lipophilicity

Water Solubility

Pharmacokinetics

Druglikeness

Medicinal Chemistry

Application In Synthesis of [ 27143-07-3 ]

[ 27143-07-3 ] Synthesis Path-Downstream 1~55

Related Products

Historical Records

Technical Information

Categories

Pharmaceutical Intermediates of [ 27143-07-3 ]

Apixaban Related Intermediates

Related Functional Groups of [ 27143-07-3 ]

Aryls

Chlorides

Ethers

Esters

Amines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Pharmaceutical Intermediates of
[ 27143-07-3 ]

Related Functional Groups of
[ 27143-07-3 ]